

WOCKHARDT'S TRANSFORMATION

Amongst the Top 3 Indian Pharma Companies


with

95% Growth in Profit After Tax at Rs.378 crores

61% Growth in EBITDA at Rs. 502 crores

35% Growth in Revenues at Rs. 1426 crores

in 1st Quarter of 2012-13



PRESS RELEASE



Wockhardt Limited
| Wockhardt Towers |
| Bandra Kurla Complex |
| Mumbai 400 051 | India |
| Tel.: +91-22-2653 4444 |
| www.ockhardt.com

	Q1FY13		Q1FY12	Q4FY12	FY12
	Apr - Jun 2012		Apr-Jun 2011	Jan-Mar 2012	
	Rsc	Gwth Y-O-Y	Rsc	Rsc	Rsc
Sales	1,426	35%	1,053	1,241	4,614
EBITDA	502	61%	312	429	1,440
EBITDA Margins %	35%		30%	35%	31%
PAT	378	95%	194	(192)	343
PAT Margins	27%		18%		7%
Adjusted PAT	383	97%	194	410	947
PAT Margins %	27%		18%	33%	21%
EPS (Adj. PAT)	35.0	97%	17.8	37.5	86.5

Wockhardt Limited, the Pharmaceutical and Biotechnology major, delivered 95% increase in Profit After Tax at Rs.378 crores in 1st Quarter of financial year 2012-13. The EBITDA at Rs.502 crores grew by 61% and represented 10th consecutive quarter of sequential growth. This sustained EBITDA and PAT performance, both in terms of value and margins, now ushers Wockhardt amongst the Top 3 Best Performing Indian Pharma companies.

Consolidated revenues grew by 35% to Rs.1,426 Crores over the corresponding quarter of Financial Year 2011-12. This represented 5th consecutive quarter of sequential growth in consolidated revenues. Wockhardt's US and EU operations have been the major contributor in its growth and the momentum continued in this quarter as they contributed to 71% of consolidated revenues.

US business recorded a spectacular growth of 78% (45% on \$ basis) compared to the corresponding quarter of Financial Year 2011-12. The US business launched the authorized generic version of Stalevo® for which it had received FTF status earlier and 2 OTC products during the quarter.

PRESS RELEASE



Wockhardt Limited
| Wockhardt Towers |
| Bandra Kurla Complex |
| Mumbai 400 051 | India |
| Tel.: +91-22-2653 4444 |
| www.ockhardt.com

The UK business recorded a growth of 31% (11% on £ basis) compared to the corresponding quarter of Financial Year 2011-12 in an otherwise stagnant market. In the quarter the UK and Irish markets launched the generic Atorvastatin which is expected to be a key product for both UK and Irish businesses.

Wockhardt's R&D continued its multidisciplinary research and patent filings across its 3 R&D centers worldwide employing 578 scientists. The company now has a total of 164 Patents granted and has filed for a total of 1585 Patents Globally. It has received the Government of India and Pharmexcil award for maximum patents filing for 3 years in a row. The company markets 475 products in the regulated markets manufactured in its India, USA, UK and Ireland facilities.

Late Dr. Abid Hussain, India's former ambassador to USA and a non executive director on the board of Wockhardt passed away on June 21st 2012. Wockhardt has appointed Dr. Sanjaya Baru, a noted economist and former media advisor to the Prime Minister of India and Mr. D S Brar, ex CEO and MD of Ranbaxy, as non executive directors on the board.

Wockhardt recently concluded the divestment of its Nutrition business to Danone for Rs.1280 crores. This has significantly improved the balance sheet position for the company and its Net Debt to Equity ratio now stands below 1.

PRESS RELEASE



Wockhardt Limited
| Wockhardt Towers |
| Bandra Kurla Complex |
| Mumbai 400 051 | India |
| Tel.: +91-22-2653 4444 |
| www.wockhardt.com

Peer Group Comparison

Q1FY13 Financial Results

Summary (Rsm)	Dr Reddys	Glenmark	Wockhardt	Lupin	Cipla	Biocon
Sales	2,541	1,041	1,426	2,254	2,012	577
Sales Growth	28%	20%	35%	44%	24%	30%
EBITDA	499	165	502	458	563	123
EBITDA Growth	24%	-44%	61%	55%	47%	0%
EBITDA Margins	20%	16%	35%	20%	28%	21%
PAT	336	78	378	280	401	79
PAT Growth	28%	-62%	95%	33%	58%	12%
PAT%	13%	8%	27%	12%	20%	14%